Skip to main content
. Author manuscript; available in PMC: 2022 Dec 12.
Published in final edited form as: Ann Oncol. 2019 Dec 9;31(3):412–421. doi: 10.1016/j.annonc.2019.11.018

Figure 3. Mutational profile of selected oncogenic alterations in patients with advanced salivary gland carcinoma (n =19).

Figure 3.

BOR, best overall response; CR, complete response; HER2, human epidermal growth factor receptor 2; PD, progressive disease; PR, partial response; SD, stable disease; TMB, tumor mutational burden.